Biomarkers market set for 11% CAGR on early detection push

The market was valued at $26.48b in 2025. 

The global cancer biomarkers market is projected to grow at a compound annual growth rate of 11.2% between 2026 and 2034, following its market valuation of $26.48b in 2025, according to Polaris Market Research.

Asia-Pacific is expected to register the fastest growth in the market as healthcare systems expand access to diagnostic services and increase spending on early cancer detection.

Cancer biomarkers include biological indicators such as DNA, RNA, proteins, and metabolites that help detect cancer, assess disease progression, and monitor treatment response.

Their use spans diagnosis, prognosis, and therapy selection across multiple cancer types.

Genetic biomarkers account for the largest share by type, supported by their use in targeted therapies, whilst breast, lung, prostate, and colorectal cancers remain the main application areas.

Diagnostic use accounts for the largest share, followed by prognostics and drug discovery.

Hospitals and diagnostic laboratories represent the main end users, whilst pharmaceutical companies are increasing use in research and development.

Liquid biopsy adoption continues to expand as an alternative to tissue biopsy, where it uses blood samples to detect circulating tumour DNA, exosomes, and circulating tumour cells.

This enables repeat testing and real-time monitoring of disease progression and treatment response.

Technologies including next-generation sequencing, high-throughput screening, and multi-omics platforms support biomarker discovery.

Artificial intelligence and machine learning systems process large datasets to identify cancer patterns and support patient stratification for treatment selection.

Pharmaceutical companies integrate biomarkers into drug development to improve clinical trial design and reduce failure rates, whilst companion diagnostics now form part of oncology drug approval pathways in targeted therapies.

Market participants invest in research and development of biomarker assays and oncology platforms, with companies pursuing collaboration and consolidation to expand product portfolios and clinical applications.